The lack of substantial support might be about CFE's track record over the last decade, plus the reputations of certain company heavies.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025